| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1376 | |
| Phytochemical name or plant extracts | Sutherlandia frutescens extract | |
| PMID | 17433588 | |
| Literature evidence | A statistically significant decrease to 50% of malignant cell numbers was observed after 24 h of exposure to 1.5 mg/ml Sutherlandia frutescens extract when compared to vehicle-treated controls. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Sutherlandia frutescens | |
| Geographical availability | Botswana, Cape Provinces, Free State, KwaZulu-Natal, Lesotho, Namibia, Northern Provinces | |
| Plant parts | Leaves and twigs | |
| Other cancers | Breast cancer | |
| Target gene or protein | MEK5, PIAS1 , SMPD3, MMP16, MMP21, MYC2L | |
| Gene or Protein evidence | Causes downregulation of the MEK5 gene leading to attenuation of the MEK5-BMK1/ERK5 pathway, . Causes downregulation of PIAS1 gene, upregulation of sphingomyelinase-2 (SMPD3) gene, formation of ceramide, downregulation of several metalloproteinases (MMP) including MMP-16 and MMP-21. It can be seen that the MYC2L gene expression was downregulated. (MCF-7 cells) | |
| Target pathways | MEK5-BMK1/ERK5 pathway | |
| IC50 | 1.5 mg/ml against MCF-7 | |
| Potency | NA | |
| Cell line/ mice model | MCF-7 | |
| Additional information | Flow cytometry showed an increase in the sub G(1) apoptotic fraction and an S phase arrest in both the 5 mg/ml and 10 mg/ml S. frutescens-treated cells. | |
| PubChem ID | NA | |
| Additional PMIDs | 19527821 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:1017425-1 | |
| Safety | NA |